Former executive at Aenova Holding GmbH
- European CDMOs (contract development and manufacturing organisations) and CROs (contract research organisations) – ongoing market pressures including supply chain, labour and cost pass-through dynamics
- Aenova’s competitive positioning and performance update across key end markets, including oral solids and soft gels
- Aenova’s key growth drivers, including injectable formulations and other differentiated technologies, and growth ability in steriles, HP-APIs (highly potent active pharmaceutical ingredients) and other end markets
- European CDMO 2023 outlook
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.